CGTX — COGNITION THERAPEUTICS INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1455365 ·
Last close
$0.94
Market Cap
$89.10M
52W High
$2.05
52W Low
$0.55
ADV30
406,033
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 0 | — | -4,838,000 | -4,570,000 | 36,140,000 | 31,130,000 | 6,229,000 |
| Dec 2025 | 0 | — | -3,672,000 | -3,343,000 | 48,390,000 | 36,810,000 | 14,119,000 |
| Sep 2025 | 0 | — | -5,160,000 | -4,930,000 | 43,395,000 | 39,334,000 | 6,866,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-20,253,000
Investing CF
$9,000
Financing CF
$35,041,000
CapEx
$-1,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.26
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-203,217,000
Inventory
—
Receivables
$3,657,000
ST Investments
—
EBIT TTM
$-19,564,000
Pretax Income TTM
$-19,577,000
Interest Exp TTM
$13,000
Analysts
3
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -24,393,000 | -23,487,000 | 48,390,000 | 14,119,000 | 34,271,000 | -24,588,000 |
| Dec 2024 | 0 | -34,417,000 | -33,971,000 | 30,234,000 | 11,484,000 | 18,750,000 | -28,474,000 |
| Dec 2023 | 0 | -25,919,000 | -25,788,000 | 35,163,000 | 10,689,000 | 24,474,000 | -16,018,000 |
| Dec 2022 | 0 | -21,334,000 | -21,397,000 | 50,425,000 | 10,176,000 | 40,249,000 | -18,533,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.22
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ATRA | Atara Biotherapeutics, Inc. | $88.43M | $8.81 | — |
| PTHS | Pelthos Therapeutics Inc. | $84.95M | $22.19 | — |
| CRDF | Cardiff Oncology, Inc. | $96.47M | $1.24 | — |
| CLLS | Cellectis S.A. | $106.90M | $1.47 | — |
| BSEM | BioStem Technologies, Inc. | $73.82M | $4.14 | — |
News headlines (Yahoo Finance, 1h cache)
Cognition Therapeutics to Present at H.C. Wainwright Global Investment Conference
2026-09-08 11:30 · Yahoo
Cognition Therapeutics, Inc. (CGTX) Reports Q2 Loss, Lags Revenue Estimates
2026-08-06 23:10 · Yahoo
Cognition Therapeutics Reports Financial Results for the Second Quarter 2026 and Provides Business Update
2026-08-06 20:15 · Yahoo
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
2026-07-13 11:30 · Yahoo
Cognition Therapeutics Gets Positive FDA Feedback Over Phase 3 Study Of DLB Psychosis – But CGTX Stock Just Crashed 33%
2026-06-24 15:47 · Yahoo
Cognition Therapeutics Advances After FDA Supports Key Elements of Pivotal Trial Plan (CGTX)
2026-06-24 12:46 · Yahoo
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
2026-06-16 11:30 · Yahoo
Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies?
2026-06-02 13:56 · Yahoo
Cognition Therapeutics Participating in Upcoming Investor Conferences
2026-06-01 11:30 · Yahoo
Cognition Therapeutics Receives Second Philanthropic Donation to Extend Ongoing Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies
2026-05-14 11:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.